TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
TRIMTECH Therapeutics has raised $14.0M in total funding. The most recent round was Seed. The last funding was announced in June 2026.
TRIMTECH Therapeutics's investors include Eli Lilly, Business Growth Fund, Cambridge Innovation Capital, Dementia Discovery Fund, Johnson & Johnson Innovation.
TRIMTECH Therapeutics is headquartered in Cambridge, United States.
TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
TRIMTECH Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TRIMTECH Therapeutics — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/trimtech-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). TRIMTECH Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/trimtech-therapeutics
{{cite web |title=TRIMTECH Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/trimtech-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated